$86 Million

Scholar Rock

Initial Public Offering

Bookrunner, May 2018

Scholar Rock Holding Corp is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The Company is actively advancing its lead and wholly owned product, SRK-015, a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle, into clinical development for the treatment of spinal muscular atrophy, or SMA. Beyond SRK-015, Scholar Rock’s second antibody program is focused on the discovery and development of highly specific inhibitors of the activation of Transforming Growth Factor Beta 1, or TGFβ1